FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:214-215 January 20, 2000 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by De Stefano, V. PubMed Citation

To the Editor: De Stefano and colleagues (Sept. 9 issue)¹ reported the results of their retrospective analysis of the risk of recurrent deep venous thrombosis in patients with deep venous thrombosis who were heterozygous for both factor V Leiden and the G20210A prothrombin mutation. On the basis of this analysis, they recommend lifelong treatment with vitamin K antagonists for all patients with these two defects. We are concerned about this recommendation for two reasons. First, the absolute risk of recurrent deep venous thrombosis observed in this study appears to be spuriously high. Second, depending on the specific characteristics of the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vaya, A., Todoli, J., Ricart, J., Estelles, A., Mira, Y., Villa, P., Calabuig, J. R., Aznar, J. (2001). Upper Extremity Deep Vein Thrombosis in a Young Patient Double Heterozygous for Factor V Leiden and Prothrombin G20210A Mutation. CLIN APPL THROMB HEMOST 7: 72-74 [Abstract]